The wholly-owned subsidiary has received approval from Japan#39;s Ministry of Health, Labour and Welfare for Ilumya (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies, Sun Pharmaceutical Industries said in filing to BSE.Sun Pharma gets nod from Japan govt for plaque psoriasis treatment drug
The wholly-owned subsidiary has received approval from Japan#39;s Ministry of Health, Labour and Welfare for Ilumya (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies, Sun Pharmaceutical Industries said in filing to BSE.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment